The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation.

Neuroblastoma is an embryonal tumor of the sympathetic nervous system and the most common extracranial tumor of childhood. By sequencing transcriptomes of low- and high-risk neuroblastomas, we detected differentially expressed annotated and nonannotated long noncoding RNAs (lncRNAs). We identified a lncRNA neuroblastoma associated transcript-1 (NBAT-1) as a biomarker significantly predicting clinical outcome of neuroblastoma. CpG methylation and a high-risk neuroblastoma associated SNP on chromosome 6p22 functionally contribute to NBAT-1 differential expression. Loss of NBAT-1 increases cellular proliferation and invasion. It controls these processes via epigenetic silencing of target genes. NBAT-1 loss affects neuronal differentiation through activation of the neuronal-specific transcription factor NRSF/REST. Thus, loss of NBAT-1 contributes to aggressive neuroblastoma by increasing proliferation and impairing differentiation of neuronal precursors.

[1]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[2]  R. Arceci.  The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report , 2009 .

[3]  H. Hakonarson,et al.  Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma , 2012, Nature Genetics.

[4]  B. Karlan,et al.  ACollagen-Remodeling Gene Signature Regulated by TGF-b Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer , 2014 .

[5]  Howard Y. Chang,et al.  Long Noncoding RNAs: Cellular Address Codes in Development and Disease , 2013, Cell.

[6]  M. Jackson,et al.  Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Rosenquist,et al.  ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia , 2013, Epigenetics.

[8]  C. Kanduri.  Long noncoding RNA and epigenomics. , 2011, Advances in experimental medicine and biology.

[9]  Staffan Nilsson,et al.  High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset , 2010, Proceedings of the National Academy of Sciences.

[10]  D. Gary Gilliland,et al.  Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.

[11]  F. Westermann,et al.  Risk Estimation of Neuroblastoma Patients Using Molecular Markers , 2008, Klinische Padiatrie.

[12]  H. Caron,et al.  Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. , 1995, Medical and pediatric oncology.

[13]  Manuel Serrano,et al.  Oncogenicity of the developmental transcription factor Sox9. , 2012, Cancer research.

[14]  Raymond K. Auerbach,et al.  Extensive Promoter-Centered Chromatin Interactions Provide a Topological Basis for Transcription Regulation , 2012, Cell.

[15]  Gudrun Schleiermacher,et al.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.

[16]  K. Pollard,et al.  Detection of nonneutral substitution rates on mammalian phylogenies. , 2010, Genome research.

[17]  H. Carén,et al.  High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. , 2008, The Biochemical journal.

[18]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[19]  Michael-John Dolan,et al.  CHD5 is required for neurogenesis and has a dual role in facilitating gene expression and polycomb gene repression. , 2013, Developmental cell.

[20]  John T. Wei,et al.  Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression , 2011, Nature Biotechnology.

[21]  A. Chinnaiyan,et al.  The emergence of lncRNAs in cancer biology. , 2011, Cancer discovery.

[22]  F. Westermann,et al.  Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma , 2013, Cell Death and Disease.

[23]  M. Birrer,et al.  Microenvironment and Immunology TGF-b Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment , 2013 .

[24]  William Stafford Noble,et al.  Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors , 2012, Genome research.

[25]  Giovanni Parmigiani,et al.  Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma , 2012, Nature Genetics.

[26]  J. Kocher,et al.  CPAT: Coding-Potential Assessment Tool using an alignment-free logistic regression model , 2013, Nucleic acids research.

[27]  J. Khan,et al.  EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. , 2012, Cancer research.

[28]  R. Spizzo,et al.  Long non-coding RNAs and cancer: a new frontier of translational research? , 2012, Oncogene.

[29]  L. Murphy,et al.  Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer. , 2012, Endocrine-related cancer.

[30]  M. Schwab.  Amplification of oncogenes in human cancer cells , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[31]  Steven J. M. Jones,et al.  The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.

[32]  K. Aldape,et al.  Abnormal Expression of REST/NRSF and Myc in Neural Stem/Progenitor Cells Causes Cerebellar Tumors by Blocking Neuronal Differentiation , 2006, Molecular and Cellular Biology.

[33]  J. Borén,et al.  Targeting filamin A reduces K-RAS–induced lung adenocarcinomas and endothelial response to tumor growth in mice , 2012, Molecular Cancer.

[34]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[35]  Giovanni Cecchetto,et al.  The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Brodeur.  Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.

[37]  D. Zwijnenburg,et al.  Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes , 2012, Nature.

[38]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[39]  A. Cantor,et al.  Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. , 1993, The New England journal of medicine.

[40]  A. Nakagawara,et al.  Molecular and genetic bases of neuroblastoma , 2012, International Journal of Clinical Oncology.

[41]  Gaurav Kumar Pandey,et al.  Regulation of the mammalian epigenome by long noncoding RNAs. , 2009, Biochimica et biophysica acta.

[42]  D. Stram,et al.  Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas , 1999, Oncogene.

[43]  Howard Y. Chang,et al.  Cytotopic localization by long noncoding RNAs. , 2013, Current opinion in cell biology.

[44]  K. Jensen,et al.  Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[45]  Nazneen Rahman,et al.  Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. , 2008, The New England journal of medicine.

[46]  F. Berthold,et al.  Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  S. Ogawa,et al.  Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.

[48]  J. Mattick,et al.  Non‐coding RNAs: regulators of disease , 2010, The Journal of pathology.

[49]  H. Carén,et al.  High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A gene , 2008, BMC Genomics.